Date: 2014-01-13
Type of information: Production agreement
Compound: Imbruvica™ (ibrutinib)
Company: Lonza (Switzerland) Pharmacyclics (USA)
Therapeutic area: Cancer - Oncology
Type agreement: manufacturing
production
Action mechanism: tyrosine kinase inhibitor/Bruton's tyrosine kinase inhibitor. Imbrivuca™ is a first-in-class, oral therapy and is a new agent that inhibits a protein called Bruton's tyrosine kinase (BTK). BTK is a key signaling molecule of the B-cell receptor signaling complex that plays an important role in the survival of malignant B cells. Imbrivuca™ blocks signals that tell malignant B cells to grow and divide uncontrollably.
Disease:
Details: * On January 13, 2014, Lonza has announced it has established an agreement with Pharmacyclics, to support the commercial and clinical production of its first-in-class oral oncology drug, Imbrivuca™ (Ibrutinib). This agreement follows a successful multi-year partnership, including the development and clinical manufacturing, which was utilized for Pharmacyclics’ NDA submission and now first FDA approval of their lead product for oncology treatment. Under the long term agreement, Lonza will continue to support the production of commercial and clinical material. Pharmacyclics received final FDA approval of Imbrivuca™on 13 November 2013 for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.
Financial terms:
Latest news:
